Sugi Predict

Sugi Predict / Compounds / SCHEMBL657651

SCHEMBL657651

SCHEMBL657651

CC(C)(C)[Si](C)(C)O[C@H]1CC[C@H](n2cc(I)cn2)CC1

nearest known ligand 0.43

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 1/20 0.43
▸ MET P08581 2/20 0.42
▸ RET P07949 1/20 0.32
▸ ACHE P22303 1/20 0.31
▸ KDM5B Q9UGL1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657652 1.00 MPO (0.43) MPOMETRETACHEKDM5B
SCHEMBL2028023 0.87 MPO (0.41) MPOMET
SCHEMBL660315 0.81 MET (0.41) METRETACHE
SCHEMBL660314 0.81 MET (0.41) METRETACHE
SCHEMBL658738 0.79 FFAR1 (0.43) MET
SCHEMBL659363 0.79 FFAR1 (0.43) MET
SCHEMBL670597 0.78 — —
SCHEMBL31392849 0.77 MPO (0.37) MPO
SCHEMBL1357653 0.75 MET (0.33) MET
SCHEMBL1357654 0.75 MET (0.33) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2569314-B1 FUSED BICYCLIC KINASE INHIBITORS OSI PHARMACEUTICALS LLC (US) 2016-09-07 — — EP disclosed
US-20140088114-A1 FUSED BICYCLIC KINASE INHIBITORS OSI Pharmaceuticals ,LLC 2014-03-27 — — US disclosed
US-20140088114-A1 FUSED BICYCLIC KINASE INHIBITORS OSI Pharmaceuticals ,LLC 2014-03-27 — — US disclosed
US-20140088114-A1 FUSED BICYCLIC KINASE INHIBITORS OSI Pharmaceuticals ,LLC 2014-03-27 — — US disclosed
US-20130253197-A1 FUSED BICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, LLC (US) 2013-09-26 — — US disclosed
US-8445510-B2 Fused bicyclic kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-05-21 — — US disclosed
US-20130072495-A1 FUSED BICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, LLC 2013-03-21 — — US disclosed
US-8378104-B2 7-aminofuropyridine derivatives OSI Pharmaceuticals, LLC (US) 2013-02-19 — — US disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 — — US disclosed
US-20110281888-A1 Fused Bicyclic Kinase Inhibitors OSI Pharmaceuticals, LLC 2011-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281888-A1 Fused Bicyclic Kinase Inhibitors ALK, RET, MET MPO 4233/4885MET 3/4885RET 2/4885
US-20130253197-A1 FUSED BICYCLIC KINASE INHIBITORS ALK, RET, MET MPO 4233/4885MET 3/4885RET 2/4885
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES MAP3K5, STK17A, MAPKAPK5 MPO 3843/4885MET 1182/4885RET 588/4885
US-20130072495-A1 FUSED BICYCLIC KINASE INHIBITORS IGF1R, MET, ALK MPO 4657/4885MET 2/4885RET 4/4885
US-20140088114-A1 FUSED BICYCLIC KINASE INHIBITORS IGF1R, MET, RET MPO 4641/4885MET 2/4885RET 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.